Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40–60 years

@article{Cornelissen2015ComparativeTV,
  title={Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40–60 years},
  author={Jan B. W. J. Cornelissen and Jurjen Versluis and Jakob Robert Passweg and Wim L. J. van Putten and Markus G. Manz and Johann Maertens and H. Berna Beverloo and Peter J. M. Valk and Marinus van Marwijk Kooy and Pierre W. Wijermans and Martijn R Schaafsma and Bart J. Biemond and M -C Vekemans and Dimitri A. Breems and Leo F. Verdonck and Martin F. Fey and Mojca Jongen-Lavrencic and J. M. J. Janssen and Gerwin Huls and Jurgen Kuball and Thomas Pabst and Carlos Graux and Harold C Schouten and Alois A Gratwohl and Edo Vellenga and G. Ossenkoppele and Bob L{\"o}wenberg},
  journal={Leukemia},
  year={2015},
  volume={29},
  pages={1041-1050}
}
The preferred type of post-remission therapy (PRT) in patients with acute myeloid leukemia (AML) in first complete remission (CR1) is a subject of continued debate, especially in patients at higher risk of nonrelapse mortality (NRM), including patients >40 years of age. We report results of a time-dependent multivariable analysis of allogenic hematopoietic stem cell transplantation (alloHSCT) (n=337) versus chemotherapy (n=271) or autologous HSCT (autoHSCT) (n=152) in 760 patients aged 40–60… CONTINUE READING